Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe inflammatory demyelinating disease of the central nervous system that often causes disability. Based on evidence from prospective and retrospective studies, Rituximab (RTX) has been used as the first-line of therapy in NMOSD. Nevertheless, e...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis and related disorders 2021-02, Vol.48, p.102683-102683, Article 102683 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102683 |
|---|---|
| container_issue | |
| container_start_page | 102683 |
| container_title | Multiple sclerosis and related disorders |
| container_volume | 48 |
| creator | Correa-Díaz, Edgar Patricio Torres-Herrán, Germaine Eleanor Miño Zambrano, Joselyn Elizabeth Paredes-Gonzalez, Víctor Caiza-Zambrano, Francisco José |
| description | Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe inflammatory demyelinating disease of the central nervous system that often causes disability. Based on evidence from prospective and retrospective studies, Rituximab (RTX) has been used as the first-line of therapy in NMOSD. Nevertheless, evidence of the impact of RTX on relapse rate and disability in Ecuadorian patients with NMOSD is lacking.
To evaluate the impact of RTX in an Ecuadorian cohort of patients with NMOSD.
A retrospective study was conducted in a cohort of patients with NMOSD who received treatment with RTX in a third-level hospital in Quito, Ecuador. Digital medical records of NMOSD patients were reviewed to attain sociodemographic data, disease characteristics, and treatment with RTX. The annualized relapse rate ARR, as well as the degree of disability measured through the expanded disability scale (EDSS), was established before and after treatment.
Twenty-three patients with NMOSD treated with RTX were included, the mean age of onset of the disease was 37.2 years (range, 13-64.5). The average duration of disease was 8.5 years (range, 1.3-34.4). Positivity for antibodies against aquaporin-4 (AQP4-IgG) was identified in 78% of the patients. The mean duration of the treatment with RTX was 40 months (range, 12-61). After the RTX therapy, the number of relapses was reduced in 91% (21/23) of cases. The annualized relapsed rate (ARR) was reduced with RTX from 1.89 to 0.12 (p |
| doi_str_mv | 10.1016/j.msard.2020.102683 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2471462010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2211034820307574</els_id><sourcerecordid>2471462010</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-b09b494e12b6807dc801033e2a7ba5ca707a11c1fcc8a49d9109de03a5d5a0e23</originalsourceid><addsrcrecordid>eNp9UctKBDEQDKKorH6BIDl62TWPeR48iPgCQRA9h56kF7PMTMYko-7ZHzezqx7tSzdNVTVdRcgJZwvOeHG-WnQBvFkIJqaNKCq5Qw6F4HzOZF7s_s1ZdUCOQ1ixVEXOs4LvkwOZqqqz_JB83XcD6Ejdkj7ZOH7aDhrqeuqxhSEg9RCRQm-osQEa29q4prZPG3qtRzDO2zRq9-r8RmOAaLGPgX7Y-Ep7HL3r1phYNlA3RKuBhgF19GM3KTpv0IcjsreENuDxT5-Rl5vr56u7-cPj7f3V5cNcy7yO84bVTVZnyEVTVKw0umKcSYkCygZyDSUrgXPNl1pXkNWm5qw2yCTkJgeGQs7I2VZ38O5txBBVZ4PGtoUe3RiUyMrkj5hUZ0Ruodq7EDwu1eCTNX6tOFNTAGqlNgGoKQC1DSCxTn8OjE2H5o_za3cCXGwBmN58t-hV0Mkvjcb65Ioyzv574BtCwpnt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471462010</pqid></control><display><type>article</type><title>Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Correa-Díaz, Edgar Patricio ; Torres-Herrán, Germaine Eleanor ; Miño Zambrano, Joselyn Elizabeth ; Paredes-Gonzalez, Víctor ; Caiza-Zambrano, Francisco José</creator><creatorcontrib>Correa-Díaz, Edgar Patricio ; Torres-Herrán, Germaine Eleanor ; Miño Zambrano, Joselyn Elizabeth ; Paredes-Gonzalez, Víctor ; Caiza-Zambrano, Francisco José</creatorcontrib><description>Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe inflammatory demyelinating disease of the central nervous system that often causes disability. Based on evidence from prospective and retrospective studies, Rituximab (RTX) has been used as the first-line of therapy in NMOSD. Nevertheless, evidence of the impact of RTX on relapse rate and disability in Ecuadorian patients with NMOSD is lacking.
To evaluate the impact of RTX in an Ecuadorian cohort of patients with NMOSD.
A retrospective study was conducted in a cohort of patients with NMOSD who received treatment with RTX in a third-level hospital in Quito, Ecuador. Digital medical records of NMOSD patients were reviewed to attain sociodemographic data, disease characteristics, and treatment with RTX. The annualized relapse rate ARR, as well as the degree of disability measured through the expanded disability scale (EDSS), was established before and after treatment.
Twenty-three patients with NMOSD treated with RTX were included, the mean age of onset of the disease was 37.2 years (range, 13-64.5). The average duration of disease was 8.5 years (range, 1.3-34.4). Positivity for antibodies against aquaporin-4 (AQP4-IgG) was identified in 78% of the patients. The mean duration of the treatment with RTX was 40 months (range, 12-61). After the RTX therapy, the number of relapses was reduced in 91% (21/23) of cases. The annualized relapsed rate (ARR) was reduced with RTX from 1.89 to 0.12 (p <0.001). The mean EDSS was also reduced from 4.8 to 3.9 (p = 0.014). In all patients, the mean EDSS was reduced or stabilized with RTX. Overall, the drug was well tolerated, the most frequent adverse events were infections which were present in 65.2% of cases.
Though with the limitations of and observational study, our data support RTX effectiveness and safety in an Ecuadorian cohort of patients with NMOSD.</description><identifier>ISSN: 2211-0348</identifier><identifier>EISSN: 2211-0356</identifier><identifier>DOI: 10.1016/j.msard.2020.102683</identifier><identifier>PMID: 33338945</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adolescent ; Adult ; Aquaporin 4 ; CD20 ; Ecuador - epidemiology ; Humans ; Immunologic Factors - therapeutic use ; Middle Aged ; myelitis ; neuromyelitis optica ; Neuromyelitis Optica - drug therapy ; Neuromyelitis Optica - epidemiology ; Prospective Studies ; Recurrence ; Retrospective Studies ; rituximab ; Rituximab - therapeutic use ; Young Adult</subject><ispartof>Multiple sclerosis and related disorders, 2021-02, Vol.48, p.102683-102683, Article 102683</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-b09b494e12b6807dc801033e2a7ba5ca707a11c1fcc8a49d9109de03a5d5a0e23</citedby><cites>FETCH-LOGICAL-c359t-b09b494e12b6807dc801033e2a7ba5ca707a11c1fcc8a49d9109de03a5d5a0e23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33338945$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Correa-Díaz, Edgar Patricio</creatorcontrib><creatorcontrib>Torres-Herrán, Germaine Eleanor</creatorcontrib><creatorcontrib>Miño Zambrano, Joselyn Elizabeth</creatorcontrib><creatorcontrib>Paredes-Gonzalez, Víctor</creatorcontrib><creatorcontrib>Caiza-Zambrano, Francisco José</creatorcontrib><title>Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders</title><title>Multiple sclerosis and related disorders</title><addtitle>Mult Scler Relat Disord</addtitle><description>Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe inflammatory demyelinating disease of the central nervous system that often causes disability. Based on evidence from prospective and retrospective studies, Rituximab (RTX) has been used as the first-line of therapy in NMOSD. Nevertheless, evidence of the impact of RTX on relapse rate and disability in Ecuadorian patients with NMOSD is lacking.
To evaluate the impact of RTX in an Ecuadorian cohort of patients with NMOSD.
A retrospective study was conducted in a cohort of patients with NMOSD who received treatment with RTX in a third-level hospital in Quito, Ecuador. Digital medical records of NMOSD patients were reviewed to attain sociodemographic data, disease characteristics, and treatment with RTX. The annualized relapse rate ARR, as well as the degree of disability measured through the expanded disability scale (EDSS), was established before and after treatment.
Twenty-three patients with NMOSD treated with RTX were included, the mean age of onset of the disease was 37.2 years (range, 13-64.5). The average duration of disease was 8.5 years (range, 1.3-34.4). Positivity for antibodies against aquaporin-4 (AQP4-IgG) was identified in 78% of the patients. The mean duration of the treatment with RTX was 40 months (range, 12-61). After the RTX therapy, the number of relapses was reduced in 91% (21/23) of cases. The annualized relapsed rate (ARR) was reduced with RTX from 1.89 to 0.12 (p <0.001). The mean EDSS was also reduced from 4.8 to 3.9 (p = 0.014). In all patients, the mean EDSS was reduced or stabilized with RTX. Overall, the drug was well tolerated, the most frequent adverse events were infections which were present in 65.2% of cases.
Though with the limitations of and observational study, our data support RTX effectiveness and safety in an Ecuadorian cohort of patients with NMOSD.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aquaporin 4</subject><subject>CD20</subject><subject>Ecuador - epidemiology</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Middle Aged</subject><subject>myelitis</subject><subject>neuromyelitis optica</subject><subject>Neuromyelitis Optica - drug therapy</subject><subject>Neuromyelitis Optica - epidemiology</subject><subject>Prospective Studies</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>rituximab</subject><subject>Rituximab - therapeutic use</subject><subject>Young Adult</subject><issn>2211-0348</issn><issn>2211-0356</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UctKBDEQDKKorH6BIDl62TWPeR48iPgCQRA9h56kF7PMTMYko-7ZHzezqx7tSzdNVTVdRcgJZwvOeHG-WnQBvFkIJqaNKCq5Qw6F4HzOZF7s_s1ZdUCOQ1ixVEXOs4LvkwOZqqqz_JB83XcD6Ejdkj7ZOH7aDhrqeuqxhSEg9RCRQm-osQEa29q4prZPG3qtRzDO2zRq9-r8RmOAaLGPgX7Y-Ep7HL3r1phYNlA3RKuBhgF19GM3KTpv0IcjsreENuDxT5-Rl5vr56u7-cPj7f3V5cNcy7yO84bVTVZnyEVTVKw0umKcSYkCygZyDSUrgXPNl1pXkNWm5qw2yCTkJgeGQs7I2VZ38O5txBBVZ4PGtoUe3RiUyMrkj5hUZ0Ruodq7EDwu1eCTNX6tOFNTAGqlNgGoKQC1DSCxTn8OjE2H5o_za3cCXGwBmN58t-hV0Mkvjcb65Ioyzv574BtCwpnt</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Correa-Díaz, Edgar Patricio</creator><creator>Torres-Herrán, Germaine Eleanor</creator><creator>Miño Zambrano, Joselyn Elizabeth</creator><creator>Paredes-Gonzalez, Víctor</creator><creator>Caiza-Zambrano, Francisco José</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202102</creationdate><title>Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders</title><author>Correa-Díaz, Edgar Patricio ; Torres-Herrán, Germaine Eleanor ; Miño Zambrano, Joselyn Elizabeth ; Paredes-Gonzalez, Víctor ; Caiza-Zambrano, Francisco José</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-b09b494e12b6807dc801033e2a7ba5ca707a11c1fcc8a49d9109de03a5d5a0e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aquaporin 4</topic><topic>CD20</topic><topic>Ecuador - epidemiology</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Middle Aged</topic><topic>myelitis</topic><topic>neuromyelitis optica</topic><topic>Neuromyelitis Optica - drug therapy</topic><topic>Neuromyelitis Optica - epidemiology</topic><topic>Prospective Studies</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>rituximab</topic><topic>Rituximab - therapeutic use</topic><topic>Young Adult</topic><toplevel>online_resources</toplevel><creatorcontrib>Correa-Díaz, Edgar Patricio</creatorcontrib><creatorcontrib>Torres-Herrán, Germaine Eleanor</creatorcontrib><creatorcontrib>Miño Zambrano, Joselyn Elizabeth</creatorcontrib><creatorcontrib>Paredes-Gonzalez, Víctor</creatorcontrib><creatorcontrib>Caiza-Zambrano, Francisco José</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis and related disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Correa-Díaz, Edgar Patricio</au><au>Torres-Herrán, Germaine Eleanor</au><au>Miño Zambrano, Joselyn Elizabeth</au><au>Paredes-Gonzalez, Víctor</au><au>Caiza-Zambrano, Francisco José</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders</atitle><jtitle>Multiple sclerosis and related disorders</jtitle><addtitle>Mult Scler Relat Disord</addtitle><date>2021-02</date><risdate>2021</risdate><volume>48</volume><spage>102683</spage><epage>102683</epage><pages>102683-102683</pages><artnum>102683</artnum><issn>2211-0348</issn><eissn>2211-0356</eissn><abstract>Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe inflammatory demyelinating disease of the central nervous system that often causes disability. Based on evidence from prospective and retrospective studies, Rituximab (RTX) has been used as the first-line of therapy in NMOSD. Nevertheless, evidence of the impact of RTX on relapse rate and disability in Ecuadorian patients with NMOSD is lacking.
To evaluate the impact of RTX in an Ecuadorian cohort of patients with NMOSD.
A retrospective study was conducted in a cohort of patients with NMOSD who received treatment with RTX in a third-level hospital in Quito, Ecuador. Digital medical records of NMOSD patients were reviewed to attain sociodemographic data, disease characteristics, and treatment with RTX. The annualized relapse rate ARR, as well as the degree of disability measured through the expanded disability scale (EDSS), was established before and after treatment.
Twenty-three patients with NMOSD treated with RTX were included, the mean age of onset of the disease was 37.2 years (range, 13-64.5). The average duration of disease was 8.5 years (range, 1.3-34.4). Positivity for antibodies against aquaporin-4 (AQP4-IgG) was identified in 78% of the patients. The mean duration of the treatment with RTX was 40 months (range, 12-61). After the RTX therapy, the number of relapses was reduced in 91% (21/23) of cases. The annualized relapsed rate (ARR) was reduced with RTX from 1.89 to 0.12 (p <0.001). The mean EDSS was also reduced from 4.8 to 3.9 (p = 0.014). In all patients, the mean EDSS was reduced or stabilized with RTX. Overall, the drug was well tolerated, the most frequent adverse events were infections which were present in 65.2% of cases.
Though with the limitations of and observational study, our data support RTX effectiveness and safety in an Ecuadorian cohort of patients with NMOSD.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33338945</pmid><doi>10.1016/j.msard.2020.102683</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2211-0348 |
| ispartof | Multiple sclerosis and related disorders, 2021-02, Vol.48, p.102683-102683, Article 102683 |
| issn | 2211-0348 2211-0356 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2471462010 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aquaporin 4 CD20 Ecuador - epidemiology Humans Immunologic Factors - therapeutic use Middle Aged myelitis neuromyelitis optica Neuromyelitis Optica - drug therapy Neuromyelitis Optica - epidemiology Prospective Studies Recurrence Retrospective Studies rituximab Rituximab - therapeutic use Young Adult |
| title | Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A18%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Rituximab%20on%20relapse%20rate%20and%20disability%20in%20an%20Ecuadorian%20cohort%20of%20patients%20with%20neuromyelitis%20optica%20spectrum%20disorders&rft.jtitle=Multiple%20sclerosis%20and%20related%20disorders&rft.au=Correa-D%C3%ADaz,%20Edgar%20Patricio&rft.date=2021-02&rft.volume=48&rft.spage=102683&rft.epage=102683&rft.pages=102683-102683&rft.artnum=102683&rft.issn=2211-0348&rft.eissn=2211-0356&rft_id=info:doi/10.1016/j.msard.2020.102683&rft_dat=%3Cproquest_cross%3E2471462010%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471462010&rft_id=info:pmid/33338945&rft_els_id=S2211034820307574&rfr_iscdi=true |